Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 67877-443

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 67877-443). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rabe-100-carton (Rabe 100 Carton)

Packaging label for Rabeprazole Sodium Delayed-Release Tablets 20 mg by Ascend Laboratories, LLC. The label includes the product name, strength, dosage form, and directions to dispense the Medication Guide. It states Rx only, package contains 100 tablets in unit dose format, and storage instructions. Manufacturer Alkem Laboratories, Mumbai, India, and distributor Ascend Laboratories, NJ, are noted. Barcode and NDC 67877-4438 appear on the label.*

FDA Label Image

Rabe-30-count (Rabe 30 Count)

Label for Rabeprazole Sodium Delayed-Release Tablets 20 mg by Ascend Laboratories, LLC. The label indicates prescription use (Rx Only) and contains 30 tablets. Storage instructions specify 25°C with permissible excursions, protection from moisture, and dispensing in tight containers. Manufacturer Alkem Laboratories Ltd. in India and distributor Ascend Laboratories, LLC in New Jersey are noted.*

FDA Label Image

Rabe-str (Rabe Str)

Chemical structure of Rabeprazole Sodium, showing its molecular arrangement including a substituted pyridine ring and a benzimidazole moiety with Na (sodium) attached.*

FDA Label Image

Rabe-str2 (Rabe Str2)

A line graph comparing mean heartburn scores over a 28-day study period among three groups: placebo, Rabeprazole 10 mg, and Rabeprazole 20 mg. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). Scores decrease for Rabeprazole groups after day 0 compared to placebo.*

FDA Label Image

Rabe-str3 (Rabe Str3)

A line graph comparing mean heartburn scores over time between placebo and Rabeprazole Sodium 20 mg groups. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores ranging from 0 to 4. The graph shows a decrease in heartburn scores after day 0, with Rabeprazole 20 mg group maintaining lower scores than placebo.*

FDA Label Image

Rabe-str4 (Rabe Str4)

Line graph depicting mean heartburn scores over a 28-day study period comparing placebo (dashed line, n=58) and Rabeprazole Sodium 20 mg (solid line, n=59). The vertical axis indicates mean scores from 0 (none) to 4 (very severe), and the horizontal axis shows study days from -14 to 28, with a marked division at day 0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.